The prevalence of duplicate participants in clinical trials poses significant risks, compromising the integrity of data and the safety of the patients involved. To delve into this matter, we spoke with Kerri Weingard, a seasoned veteran in the field and the co-founder of Verified Clinical Trials (VCT), who brings a wealth of knowledge and experience. In this …
January 30, 2025 07:07 ET | Source: Velocity Clinical Research, Inc.Follow DURHAM, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) — Velocity Clinical Research, the leading multi-specialty clinical research organization, has partnered with Verified Clinical Trials (VCT) to set a new benchmark for patient safety and data quality in clinical trials through a new technological implementation at Velocity’s 80+ …
In the dynamic world of clinical research, ensuring data integrity and participant safety is paramount. One of the most significant challenges faced by clinical trials today is the issue of duplicate subjects in clinical trials—participants who enroll in multiple studies simultaneously or consecutively without proper washout periods. This practice can jeopardize study outcomes, compromise data …
We’re excited to announce that Verified Clinical Trials (VCT) will be exhibiting and hosting a special panel discussion focused on the growing challenges of duplicate and professional subjects in vaccine clinical trials. Vaccine clinical trials present a unique set of challenges, particularly when it comes to subject verification. Unlike many other clinical studies, vaccine trials …
Interest in decentralized clinical trials has increased and has become quite popular. The adoption of these methods became acutely more appealing and necessary during the pandemic. Many research sites and clinical trial sponsors have adopted decentralized clinical trial methods. But decentralized clinical trials also come with unique challenges. To keep clinical trials safe, compliant, and effective, …
Vaccine clinical trials pose unique challenges with regards to duplicate research subjects or professional subjects. Typically, large numbers of subjects are dosed at the first visit in a vaccine clinical trial. There is no way for a site or principal investigator to adequately check if the research subject is a duplicate or professional subject. Subjects …
There are many obstacles to the success of a clinical trial and duplicate research subjects, or professional research subjects are unfortunately one of them. Duplicate subjects in clinical trials results in a myriad of poor outcomes. Ultimately duplicate research subjects can result in a clinical trial failing to meet its endpoints. And now with decentralized …
Interest in decentralized clinical trials has increased and has become quite popular. The adoption of these methods became acutely more appealing and necessary during the pandemic. Many research sites and clinical trial sponsors have adopted decentralized clinical trial methods. But decentralized clinical trials also come with unique challenges. To keep clinical trials safe, compliant, and effective, …
Clinical trials rely upon speed and accuracy to deliver new drugs and medicines to the public. Limiting the potential for unwanted variables that can skew the data is critical. One of these issues is professional research subjects or duplicate subjects in clinical trials. These particular participants often times have motives to partiicapte in the particular …
Clinical research patients are compensated for their participation in clinical trials. In some therapeutic areas and types of clinical trials, the compensation for enrolling in one or more clinical trials or at multiple research sites is enough to influence patients to join more than one contemporaneously and expose themselves to multiple investigational products or multiple …
